Story

Gilead Sees Surge in Bullish Options Bets Targeting 2026 Gains

ENTHMSVIIDZHZH-TWJAKOHI
Aug 11, 20262 min read
Gilead Sees Surge in Bullish Options Bets Targeting 2026 Gains
Text size
Background

Gilead Sciences (NASDAQ: GILD) experienced a significant surge in options activity, with large, long-dated trades pointing to institutional conviction in the biotech firm's upside potential over the next two years. The structure of the trades suggests a strategic, measured bet on the company's growth rather than speculation on a short-term price spike.

A Closer Look at the Trades

Market data revealed a total options volume of 18,209 contracts, overwhelmingly dominated by bullish bets. Call options, which profit if the stock price rises, accounted for 17,303 contracts, compared to just 906 put options—a call-to-put ratio of nearly 19-to-1.

The most notable activity involved two identical large trades:

  • A 7,000-lot call spread targeting the August 2026 expiration was executed twice, for a total of 14,000 contracts.
  • This strategy involves buying the $135 strike call and simultaneously selling the $150 strike call, indicating a belief that Gilead's stock will trade within or above this range by that date.

The size of these transactions is characteristic of institutional investors, who use such defined-risk strategies to gain leveraged exposure to a stock's potential upside while capping maximum profit and loss.

What This Signals for Investors

Sample IUX Markets – In-articleAd

The focus on 2026 expirations demonstrates a long-term outlook, suggesting these investors are positioning for a fundamental re-rating of the company over time. This sentiment is reinforced by market indicators, including a "call skew" of 1.98%, which means traders are paying a premium for upside calls relative to downside puts.

At the same time, 3-month implied volatility, a measure of expected price swings, declined by 1.45 points to 29.2%. This combination of rising call premiums and falling overall volatility can indicate that while investors are bullish, they do not anticipate extreme price turbulence in the near term.

Fundamental and Technical Context

This options activity comes as Gilead's stock shows strong technical momentum, with all major moving averages signaling a "Buy," according to Investing.com analysis. Fundamentally, the company reported $29.44 billion in revenue for 2025 and recently raised its sales guidance.

However, potential headwinds exist. The company is not expected to be profitable this year due to charges related to acquisitions, and 12 analysts have recently cut their earnings estimates. Despite this, the mean analyst price target stands at $157.41, suggesting roughly 10% upside from its recent price of $135.13.

Read next

More on Stocks
Back to latest news

LATEST